| Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. | |
| | |
MedLine Citation:
|
PMID: 20500049 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Incretin-based therapies encompass two new classes of antidiabetic drugs: glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide, exenatide, and exenatide long-acting release), which are structurally related to GLP-1, and the dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin and saxagliptin), which limit the breakdown of endogenous GLP-1. To evaluate the safety and effectiveness of incretin-based therapies for the treatment of type 2 diabetes mellitus and the role of these therapies in clinical practice, a MEDLINE search (January 1985-November 2009) was conducted. Relevant references from the publications identified were also reviewed. Of 28 studies identified, 22 were randomized controlled trials. Data show that these therapies affect insulin secretion in a glucose-dependent manner, achieving clinically meaningful reductions in hemoglobin A(1c) levels, with very low rates of hypoglycemia. In addition, reductions in body weight have been observed with GLP-1 receptor agonists, which also exert a pronounced effect on systolic blood pressure. Various human and animal studies show that GLP-1 improves beta-cell function and increases beta-cell proliferation in vitro, which may slow disease progression. Thus, incretin-based therapies represent a promising addition to the available treatments for type 2 diabetes. |
| | |
Authors:
|
Scott R Drab |
Related Documents
:
|
1001849 - Response of gastric inhibitory polypeptide (gip) to test meal in chronic pancreatitis--... 9568699 - Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of th... 10672909 - Glp-1-analogues resistant to degradation by dipeptidyl-peptidase iv in vitro. 3880559 - Immunoreactive gastric inhibitory polypeptide response to a meal during the first eight... 12673779 - Glp-1 receptor agonists are growth and differentiation factors for pancreatic islet bet... 12777469 - Glp-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation duri... 21969479 - Use of outcomes in monitoring healthcare - how many outcome measures are needed in moni... 3308579 - Buffy coat transfusions in early type i diabetes. 15959819 - Influences of chronic and current season grazing by collared pikas on above-ground biom... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Pharmacotherapy Volume: 30 ISSN: 1875-9114 ISO Abbreviation: Pharmacotherapy Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-26 Completed Date: 2010-09-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8111305 Medline TA: Pharmacotherapy Country: United States |
Other Details:
|
Languages: eng Pagination: 609-24 Citation Subset: IM |
Affiliation:
|
University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, USA. drab@pitt.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Diabetes Mellitus, Type 2 / drug therapy* Dipeptidyl-Peptidase IV Inhibitors / administration & dosage, adverse effects, pharmacology, therapeutic use* Humans Hypoglycemic Agents / administration & dosage, adverse effects, pharmacology, therapeutic use* Incretins / administration & dosage, adverse effects, pharmacology, therapeutic use* Models, Molecular Randomized Controlled Trials as Topic Receptors, Glucagon / agonists |
| Chemical | |
Reg. No./Substance:
|
0/Dipeptidyl-Peptidase IV Inhibitors; 0/Hypoglycemic Agents; 0/Incretins; 0/Receptors, Glucagon; 0/glucagon-like peptide receptor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Urate-lowering therapy for gout: focus on febuxostat.
Next Document: Community-based rehabilitation and health professional practice: developmental opportunities and cha...